pharma · Recurrent Cervical Carcinoma
Lei Li
Lei Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Recurrent Cervical Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this ent
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Chemotherapy plus apatinib
Phase 2 · small molecule · Recurrent Cervical Carcinoma
Chemotherapy plus apatinib for Recurrent Cervical Carcinoma is a Phase 2 program (small_molecule) at Lei Li with 1 ClinicalTrials.gov record(s).
Internal code REPACC-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lei Li
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Recurrent Cervical Carcinoma
- Status
- completed
- Trials
- 1